Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.39 |
| ▸ | MLYCD | O95822 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28052660 | 0.90 | LMNA (0.37) | LMNAMGLLSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL685931 | 0.85 | LMNA (0.47) | LMNAMGLLSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL686028 | 0.85 | LMNA (0.47) | LMNAMGLLSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL12018633 | 0.85 | LMNA (0.47) | LMNAMGLLSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL686209 | 0.85 | LMNA (0.47) | LMNAMGLLSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL24142224 | 0.83 | LMNA (0.46) | LMNAMGLLSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL685740 | 0.82 | LMNA (0.44) | LMNAMGLLSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13477592 | 0.82 | LMNA (0.49) | LMNAMGLLSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL19335252 | 0.81 | CNR2 (0.34) | LMNA | |
| SCHEMBL24142152 | 0.81 | LMNA (0.43) | LMNAMGLLSLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173350-B2 | Oxime compound and resist composition containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20100021847-A1 | Oxime Compound and Resist Composition Containing the Same | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021847-A1 | Oxime Compound and Resist Composition Containing the Same | CYC1, UQCRB, CBR1 | LMNA 1922/4885MGLL 3867/4885SLC1A3 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.